MilliporeSigma, the US and Canada Life Science business of Merck, Darmstadt Germany, has announced the expansion of its facility in Lenexa, Kansas, adding 98,000 sqft of lab space and production capability to manufacture cell culture media.
"The Lenexa expansion reflects our commitment to meeting the dynamic needs of our customers worldwide and delivering on our growth plans," said Darren Verlenden, Head of Process Solutions, Life Science. "This expansion makes Lenexa the company's largest dry powder cell culture media facility in North America. Investing in the region reflects our strategy to expand and diversify our supply chain to ensure we meet current and future demand for cell culture media."
Cell culture media is an essential raw material used in the manufacture of life-saving therapies and in processes as varied as vaccine manufacturing, gene therapy, and monoclonal antibody manufacturing. Because of its central role in biomanufacturing, a consistent supply of high-quality media is required to deliver the necessary concentration and protein quality for therapeutics.
"Governor Kelly's administration knows that supporting private sector efforts to strengthen supply chains benefits Kansas workers," said David Toland, Kansas Lieutenant Governor and Secretary of Commerce. "These new opportunities at MilliporeSigma will allow even more families throughout the region to prosper."
The new production line represents the company's vision for our Lenexa site, as it was initially constructed for three manufacturing lines for dry powder cell culture media
- Darren Verlenden, Head of Process Solutions
The company's strategic investments to expand capacity with the new dry powder media manufacturing lines in existing production facilities in the Lenexa, Kansas, and Nantong, China, sites will increase both local and global production capacity to meet current demand and ensure supply for future demand surges, ensuring for future supply robustness.
"As our customers' needs and technologies evolve, so must we. The new production line represents the company's vision for our Lenexa site, as it was initially constructed for three manufacturing lines for dry powder cell culture media," said Darren. "The new production line is the culmination of multiple years of planning, and now we are able to offer greater flexibility and faster cell culture media manufacturing for our customers."
The company has a total of three centres of excellence for dry powder cell culture media manufacturing: in addition to the site in Lenexa, Kansas, serving the Americas region, and Nantong, China, for the Asia Pacific region, the third site is located in Irvine, Scotland, serving Europe, the Middle East and Africa region.
